Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. - Jones GM; Nock MK. (2022)

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. - Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; et al. (2022)

Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression. - Altman BR; Earleywine M; De Leo J. (2022)

Rats hallucinate in a similar manner to humans after psilocin - Vejmola Č.; Syrová K.; Šíchová K.; Vlastimil K.; Klučková T.; Kelemen E.; Páleníček T. (Neuroscience Applied, 2021)

Unravelling a New Conformer of Psilocin Through Computational Methods - Bhadoria Poonam; Venkatnarayan Ramanathan (SSRN Electronic Journal, 2021)

Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. - Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P (Current topics in behavioral neurosciences, 2021)

Dosing Psychedelics and MDMA. - Liechti ME; Holze F. (2021)

Psilocybin for the Treatment of Obsessive-Compulsive Disorders. - Ehrmann K; Allen JJB; Moreno FA. (2021)

Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. - Agin-Liebes G; Davis AK. (2021)

Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets. - Sousa TR; Rema J; Machado S; Novais F. (2021)

Psychedelic medicines for mood disorders: current evidence and clinical considerations. - Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D. (2021)

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action. - Rieser NM; Herdener M; Preller KH (Current topics in behavioral neurosciences, 2021)

The Potential of Psychedelics for End of Life and Palliative Care. - Yaden DB; Nayak SM; Gukasyan N; Anderson BT; Griffiths RR (Current topics in behavioral neurosciences, 2021)

Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples. - Sherwood AM; Kargbo RB; Kaylo KW; Cozzi NV; Meisenheimer P; Kaduk JA. (2021)

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. - Jones GM; Nock MK. (2021)

Psilocybin Conspectus: Status, Production Methods, and Considerations. - Plotnik L; Gibbs G; Graham T. (2021)

Psychedelics in the Treatment of Headache and Chronic Pain Disorders. - Schindler EAD. (2021)

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation. - Johnson MW. (2021)

Psilocybin for Trauma-Related Disorders. - Khan AJ; Bradley E; O'Donovan A; Woolley J. (2021)

[A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)]. - Kiguchi Y. (2021)

Psychedelic Identity Shift: A Critical Approach to Set And Setting. - Devenot N; Seale-Feldman A; Smith E; Noorani T; Garcia-Romeu A; Johnson MW. (2021)

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. - Raison CL; Jain R; Penn AD; Cole SP; Jain S (Frontiers in psychiatry, 2021)

Corrigendum: Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes. - Matzopoulos R; Morlock R; Morlock A; Lerer B; Lerer L (Frontiers in psychiatry, 2021)

Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default. - Yaden DB; Earp D; Graziosi M; Friedman-Wheeler D; Luoma JB; Johnson MW (Frontiers in psychology, 2021)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences. - Frymann T; Whitney S; Yaden DB; Lipson J (Frontiers in psychology, 2021)

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives. - Roseman L; Preller KH; Fotiou E; Winkelman MJ (Frontiers in pharmacology, 2021)

Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. - Kuburi S; Di Passa AM; Tassone VK; Mahmood R; Lalovic A; Ladha KS; Dunlop K; Rizvi S; Demchenko I; Bhat V. (2021)

Classic psychedelics, health behavior, and physical health. - Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB (Therapeutic advances in psychopharmacology, 2021)

The economics of psychedelic-assisted therapies: A research agenda. - Marseille E; Bertozzi S; Kahn JG (Frontiers in psychiatry, 2021)

Editorial: Old and new psychoactive substances: Pharmacology and potential applications. - Mayer FP; Luethi D; Areal LB; Sitte HH (Frontiers in psychiatry, 2021)

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? - Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ (Frontiers in psychiatry, 2021)

A systematic literature review of clinical trials and therapeutic applications of ibogaine. - Köck P; Froelich K; Walter M; Lang U; Dürsteler KM. (2021)

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis - McCartney A; McGovern H; De Foe A. (PsyArXiv, 2021)

Predictors of Psychedelic Experience: A Thematic Analysis (PsyArXiv, 2021)

A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. - McKernan K; Kane L; Helbert Y; Zhang L; Houde N; McLaughlin S. (F1000Res, 2021)

Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects - Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM. (medRxiv, 2021)

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study. - Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M. (2021)

Double-blind Placebo-controlled Naturalistic Study of Microdosing With Psilocybin: Effects on Brain Activity, Behavior, Cognition, Creativity, and Mental Health - National Council of Scientific; Technical Research; Argentina (ClinicalTrials.gov, 2021)

Beating pain with psychedelics: Matter over mind? - Elman I; Pustilnik A; Borsook D. (2021)

Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. - Pearson C; Siegel J; Gold JA. (2021)

Effects of Psilocybin in Major Depressive Disorder - Johns Hopkins University (ClinicalTrials.gov, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects - McCulloch DE; Grzywacz MZ; Madsen MK; Jensen PS; Ozenne B; Armand S; Knudsen GM; Fisher PM; Stenbæk DS. (PsyArXiv, 2021)

A Quantitative and Qualitative Report of Psilocybin Induced Mystical-Type Experiences and Their Relation to Lasting Positive Effects (PsyArXiv, 2021)

1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids? - Vilca-Melendez S; Uthaug MV; Griffin JL. (2021)

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity - Cavanna F; Muller S; de la Fuente LA; Zamberlan F; Palmucci M; Janeckova L; Kuchar M; Pallavicini C; Tagliazucchi E. (bioRxiv, 2021)

A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development. - Whitfield HJ. (2021)

P.0553 Effect of chronic microdosing of psilocin on cell proliferation and behavior in rats - Olejníková L.; Danda H.; Lhotková E.; Kútná V.; Šíchová K.; Syrová K.; Mazochová K.; Páleníček T. (European Neuropsychopharmacology, 2021)

P.0858 Psilocin induces perceptual alterations in rats: visual discrimination study - Vejmola Č.; Syrová K.; Koudelka V.; Šíchová K.; Tesař M.; Dodoková A.; Kelemen E.; Páleníček T. (European Neuropsychopharmacology, 2021)

Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use? - Gibbons WJ; McKinney MG; O'Dell PJ; Bollinger BA; Jones JA. (2021)

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. - Rucker J; Jafari H; Mantingh T; Bird C; Modlin NL; Knight G; Reinholdt F; Day C; Carter B; Young A. (2021)

Molecular insights into psychedelic drug action. - Slocum ST; DiBerto JF; Roth BL. (2021)

Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter. - Angenoorth TJF; Stankovic S; Niello M; Holy M; Brandt SD; Sitte HH; Maier J (International journal of molecular sciences, 2021)

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies - Weleff J; Akiki TJ; Barnett BS. (medRxiv, 2021)

Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. - Strumila R; Nobile B; Korsakova L; Lengvenyte A; Olie E; Lopez-Castroman J; Guillaume S; Courtet P. (2021)

Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test - Molumby M; Gaynor K; Guerin S. (PsyArXiv, 2021)

Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test (PsyArXiv, 2021)

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. - Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA. (2021)

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. - Becker AM; Holze F; Grandinetti T; Klaiber A; Toedtli VE; Kolaczynska KE; Duthaler U; Varghese N; Eckert A; Grünblatt E; Liechti ME. (2021)

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. - Rootman JM; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Kuypers KPC; Polito V; Bourzat F; Walsh Z. (2021)

Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. - Meinhardt MW; Pfarr S; Fouquet G; Rohleder C; Meinhardt ML; Barroso-Flores J; Hoffmann R; Jeanblanc J; Paul E; Wagner K; Hansson AC; Köhr G; et al. (2021)

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. - Ling S; Ceban F; Lui LMW; Lee Y; Teopiz KM; Rodrigues NB; Lipsitz O; Gill H; Subramaniapillai M; Mansur RB; Lin K; Ho R; et al. (2021)

Human behavioral pharmacology of psychedelics. - Strickland JC; Johnson MW. (2021)

[Rapid-acting antidepressants-neurobiological mechanisms of action]. - Gass P; Vasilescu AN; Inta D. (2021)

Daily briefing: Largest trial shows psilocybin is effective to treat depression. - Graham F. (2021)

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. - Doss MK; Považan M; Rosenberg MD; Sepeda ND; Davis AK; Finan PH; Smith GS; Pekar JJ; Barker PB; Griffiths RR; Barrett FS. (2021)

Policy in focus: Is psilocybin the next cannabis? - Basky G. (2021)

Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses-A Simultaneous EEG-FMRI Study. - Duerler P; Brem S; Fraga-González G; Neef T; Allen M; Zeidman P; Stämpfli P; Vollenweider FX; Preller KH. (2021)

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. - Kozlowska U; Nichols C; Wiatr K; Figiel M. (2021)

Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". - Spriggs MJ; Douglass HM; Park RJ; Read T; Danby JL; de Magalhães FJC; Alderton KL; Williams TM; Blemings A; Lafrance A; Nicholls DE; Erritzoe D; et al. (2021)

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder - Maryland Oncology Hematology; PA (ClinicalTrials.gov, 2021)

Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis - Radakovic C; Radakovic R; Peryer G; Geere J. (PsyArXiv, 2021)

Psychedelics and Mindfulness: A Systematic Review and Meta-Analysis (PsyArXiv, 2021)

Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. - Yu CL; Yang FC; Yang SN; Tseng PT; Stubbs B; Yeh TC; Hsu CW; Li DJ; Liang CS. (2021)

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. - Barnett BS; Parker SE; Weleff J. (2021)

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. - Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H. (2021)

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity. - Vejmola Č; Tylš F; Piorecká V; Koudelka V; Kadeřábek L; Novák T; Páleníček T. (2021)

Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo. - Fitzgerald PJ (International journal of molecular sciences, 2021)

Magic mushroom: all is not as it seems. - Castro BN; Prata Saraiva R; Afonso João D; Dantas Costa S (Acta chirurgica Belgica, 2021)

Analysis of Five Mushroom Toxins in Blood by UPLC-HRMS. - Liu WQ; Shi Y; Xiang P; Yu F; Xie B; Dong M; Ha J; Ma CL; Wen D. (2021)

A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. - Bogadi M; Kaštelan S. (2021)

Novel antidepressant drugs: Beyond monoamine targets. - Gonda X; Dome P; Neill JC; Tarazi FI. (2021)

The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. - Castelhano J; Lima G; Teixeira M; Soares C; Pais M; Castelo-Branco M. (2021)

Psychedelics, Sociality, and Human Evolution. - Rodríguez Arce JM; Winkelman MJ. (2021)

Rediscovering Psilocybin as an Antidepressive Treatment Strategy. - Zeiss R; Gahr M; Graf H. (2021)

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. - Aleksandrova LR; Phillips AG. (2021)

Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. - Li NX; Hu YR; Chen WN; Zhang B. (2021)

Derivatization-assisted enzyme-linked immunosorbent assay for identifying hallucinogenic mushrooms with enhanced sensitivity. - Morita I; Kiguchi Y; Oyama H; Takeuchi A; Tode C; Tanaka R; Ogata J; Kikura-Hanajiri R; Kobayashi N. (2021)

Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis. - Basedow LA; Riemer TG; Reiche S; Kreutz R; Majić T. (2021)

Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis. - Leger RF; Unterwald EM. (2021)

Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. - Kargbo RB. (2021)

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. - de Vos CMH; Mason NL; Kuypers KPC. (2021)

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. - Argento E; Christie D; Mackay L; Callon C; Walsh Z. (2021)

The Role of Psilocybin-Assisted Psychotherapy to Support Patients With Cancer: A Critical Scoping Review of the Research. - Lehto RH; Miller M; Sender J. (2021)

Treatment-Resistant Depression: Approaches to Treatment. - Kverno KS; Mangano E. (2021)

A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear. - Hagsäter SM; Pettersson R; Pettersson C; Atanasovski D; Näslund J; Eriksson E. (2021)

Blinding and expectancy confounds in psychedelic randomized controlled trials. - Muthukumaraswamy SD; Forsyth A; Lumley T. (2021)

Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. - Yaden DB; Johnson MW; Griffiths RR; Doss MK; Garcia-Romeu A; Nayak S; Gukasyan N; Mathur BN; Barrett FS (The international journal of neuropsychopharmacology, 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Well-Being. - Corneille JS; Luke D. (2021)

Therapeutic interventions for PTSD - current evidence on the the role of psychedelics - Figueiredo I; Viegas F; Ferreira F; Santos A; Ramos J; Miranda J. (2021)

Psychedelics and psychiatric disorders: A emerging role - Peixoto C; Santos F; Rego D; Medeiros H. (2021)

Treating addiction with psychedelics - are we waking up? - Miranda J; Barbosa M; Figueiredo I; Mota P; Tarelho A. (2021)

Psychedelics: A new era of treatment? - Torres S. (2021)

Effects of psilocybin-assisted therapy on treatment-resistant depression - Fraga A; Esteves-Sousa D; Facucho-Oliveira J; Albuquerque M; Costa M; Dos Santos P; Moura N; Moutinho A. (2021)

Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far? - Descalço N; Medeiros A; Santos C; Borges G. (2021)

Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. - Więckiewicz G; Stokłosa I; Piegza M; Gorczyca P; Pudlo R. (2021)

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers. - Mendes Rocha J; Rossi GN; Osório FL; Bouso Saiz JC; Silveira GO; Yonamine M; Crevelin EJ; Queiroz ME; Cecílio Hallak JE; Dos Santos RG. (2021)

Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. - Nkadimeng SM; Steinmann CML; Eloff JN. (2021)

Use of hallucinogens in Slovakia: Does it differ from global trends? - Lukačovič M; Masaryk R. (2021)

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. - Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR. (2021)

Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without. - van Dongen RM; Alderliefste GJ; Onderwater GLJ; Ferrari MD; Terwindt GM (European journal of neurology, 2021)

Pharmacologic Similarities and Differences Among Hallucinogens. - Waters K. (2021)

The cranial windows of perception. - DiBerto JF; Roth BL. (2021)

Psilocybin for Depression. - Wiley JF; Bei B. (2021)

The Potential Role of Serotonergic Hallucinogens in Depression Treatment. - Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M. (2021)

Serotonin Heteroreceptor Complexes and Their Integration of Signals in Neurons and Astroglia-Relevance for Mental Diseases. - Borroto-Escuela DO; Ambrogini P; Narvaez M; Di Liberto V; Beggiato S; Ferraro L; Fores-Pons R; Alvarez-Contino JE; Lopez-Salas A; Mudò G; Díaz-Cabiale Z; Fuxe K. (2021)

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. - Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS. (2021)

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. - Horton DM; Morrison B; Schmidt J. (2021)

A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study - King's College London (ClinicalTrials.gov, 2021)

Both partners practicing orgasmic meditation report having a mystical-type experience: results using the Mystical Experience Questionnaire - Siegel V; Emmert-Aronson B. (F1000Res, 2021)

Verbal behavior related to drug reinforcement in polysubstance cannabis users: Comparison across drugs. - Cox DJ; Johnson MW. (2021)

Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions. - Mayer CE; LeBaron VT; Acquaviva KD. (2021)

Naturalistic Entheogenics: Précis of Philosophy of Psychedelics - Letheby C. (PsyArXiv, 2021)

Naturalistic Entheogenics: Précis of Philosophy of Psychedelics (PsyArXiv, 2021)

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. - Madsen MK; Stenbæk DS; Arvidsson A; Armand S; Marstrand-Joergensen MR; Johansen SS; Linnet K; Ozenne B; Knudsen GM; Fisher PM. (2021)

Structure Elucidation and Spectroscopic Analysis of Chromophores Produced by Oxidative Psilocin Dimerization. - Lenz C; Dörner S; Sherwood A; Hoffmeister D. (2021)

Psilocybin for Depression: The ACE Model Manual - Watts R. (PsyArXiv, 2021)

Psilocybin for Depression: The ACE Model Manual (PsyArXiv, 2021)

Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. - Shao LX; Liao C; Gregg I; Davoudian PA; Savalia NK; Delagarza K; Kwan AC. (2021)

A dynamic and multilocus metabolic regulation strategy using quorum-sensing-controlled bacterial small RNA. - Bao SH; Jiang H; Zhu LY; Yao G; Han PG; Wan XK; Wang K; Song TY; Liu CJ; Wang S; Zhang ZY; Zhang DY; et al. (2021)

Sensitive quantitative analysis of psilocin and psilocybin in hair samples from suspected users and their distribution in seized hallucinogenic mushrooms - Zhou Liying; Xiang Ping; Wen Di; Shen Baohua; Wang Xin; Li Le; Deng Hongxiao; Chen Hang; Yan Hui; Shen Min; Shi Yan; Liu Wanhui (Forensic Toxicology, 2021)

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. - McCulloch DE; Madsen MK; Stenbæk DS; Kristiansen S; Ozenne B; Jensen PS; Knudsen GM; Fisher PM. (2021)

Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample. - Mans K; Kettner H; Erritzoe D; Haijen ECHM; Kaelen M; Carhart-Harris RL. (2021)

Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective? - Coppola M; Bevione F; Mondola R. (Preprints.org, 2021)

Psychedelic Assisted Therapy for Major Depressive Disorder: A Review - McCartney A; McGovern H; De Foe A. (PsyArXiv, 2021)

Psychedelic Assisted Therapy for Major Depressive Disorder: A Review (PsyArXiv, 2021)

Psilocybin: the magic medicine for depression? - Corrigan A; Burchill E; Pelton L; Marrocu A; Mazzoleni A; Shackshaft L. (2021)

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study. - Révész D; Ona G; Rossi GN; Rocha JM; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC. (2021)

A draft reference assembly of the Psilocybe cubensis genome - McKernan K; Kane LT; Crawford S; Chin C; Trippe A; McLaughlin S. (F1000Res, 2021)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. - Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR. (2021)

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials - Prochazkova L; van Elk M; Marschall JC; Rifkin BD; Fejer G; Schoen N; Fiacchino D; Kuchar M; Hommel B. (PsyArXiv, 2021)

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials (PsyArXiv, 2021)

Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses - McCulloch DE; Knudsen GM; Barrett FS; Doss M; Deco G; Carhart-Harris R; Rosas F; Preller K; Ramaekers J; Mason N; Müller F; Fisher PM. (PsyArXiv, 2021)

Further development of a liquid chromatography-high-resolution mass spectrometry/mass spectrometry-based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions. - Bambauer TP; Wagmann L; Weber AA; Meyer MR. (2021)

Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses (PsyArXiv, 2021)

Psilocybin: A brief overview for psychiatric mental health nurse practitioners. - Fradkin D. (2021)

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. - Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT. (2021)

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. - Cox DJ; Garcia-Romeu A; Johnson MW. (2021)

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders - Chao YS; Horton J. (Canadian Agency for Drugs and Technologies in Health, Ottawa (ON), 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing - Corneille JS; Luke D. (PsyArXiv, 2021)

Spontaneous Spiritual Awakenings: Phenomenology, Altered States, Individual Differences, and Wellbeing (PsyArXiv, 2021)

Psychedelics and health behaviour change. - Teixeira PJ; Johnson MW; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris RL. (2021)

Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. - Magaraggia I; Kuiperes Z; Schreiber R. (2021)

Decreased brain modularity after psilocybin therapy for depression. - Daws R; Timmerman C; Giribaldi B; Sexton J; Wall M; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R. (Research Square, 2021)

Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network (PsyArXiv, 2021)

Future Directions for Clinical Psilocybin Research: The Relaxed Symptom Network - Lewis-Healey E; Laukkonen RE; van Elk M. (PsyArXiv, 2021)

Registered clinical studies investigating psychedelic drugs for psychiatric disorders. - Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD. (2021)

An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report. - Hendin HM; Penn AD. (2021)

LSD and psilocybin flatten the brain’s energy landscape: insights from receptor-informed network control theory - Singleton SP; Luppi AI; Carhart-Harris RL; Cruzat J; Roseman L; Nutt DJ; Deco G; Kringelbach ML; Stamatakis EA; Kuceyeski A. (bioRxiv, 2021)

The Therapeutic Potential of Psilocybin. - Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L. (2021)

The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. - Gründer G; Jungaberle H. (2021)

New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review - Forstmann M; Sagioglou C. (PsyArXiv, 2021)

New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review (PsyArXiv, 2021)

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year. - Simonsson O; Hendricks PS; Carhart-Harris R; Kettner H; Osika W (Hypertension (Dallas, Tex.: 1979), 2021)

Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis? - Reynolds CF. (2021)

Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. - Davis AK; Griffiths RR. (2021)

Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. - Romeo B; Hermand M; Pétillion A; Karila L; Benyamina A (Journal of psychiatric research, 2021)

Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial. - Rocha JM; Rossi GN; de Lima Osório F; Bouso JC; de Oliveira Silveira G; Yonamine M; Campos AC; Bertozi G; Cecílio Hallak JE; Dos Santos RG. (2021)

Psilocybin and MDMA for the treatment of trauma-related psychopathology. - Bird CIV; Modlin NL; Rucker JJH. (2021)

Effects of the putative antidepressant psilocin on the lipid-raft proteome and lipid-raft signaling - Senese Nicolas; Nguyen Thu; Cologna Stephanie; Rasenick Mark (The FASEB Journal, 2021)

Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study. - van Elk M; Fejer G; Lempe P; Prochazckova L; Kuchar M; Hajkova K; Marschall J. (2021)

Characterization of Altered Waking States of Consciousness in Healthy Humans - University of Zurich (ClinicalTrials.gov, 2021)

Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2021)

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. - Cumming P; Scheidegger M; Dornbierer D; Palner M; Quednow BB; Martin-Soelch C. (2021)

Psilocybin: From Serendipity to Credibility? - Rucker JJ; Young AH. (2021)

[Efficacy of psychedelics in psychiatry, a systematic review of the literature]. - Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A. (2021)

Multi-locus identification of Psilocybe cubensis by high-resolution melting (HRM). - Zhang X; Yu H; Wang Z; Yang Q; Xia R; Qu Y; Tao R; Shi Y; Xiang P; Zhang S; Li C. (2021)

Spontaneous and deliberate creative cognition during and after psilocybin exposure. - Mason NL; Kuypers KPC; Reckweg JT; Müller F; Tse DHY; Da Rios B; Toennes SW; Stiers P; Feilding A; Ramaekers JG. (2021)

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies - Gard DE; Pleet MM; Bradley ER; Penn A; Gallenstein ML; Riley LS; DellaCrosse M; Garfinkle E; Michalak EE; Woolley JD. (medRxiv, 2021)

Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI) - Dworatzyk K; Jansen T; Schmidt TT. (PsyArXiv, 2021)

Phenomenological assessment of psychedelic induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI) (PsyArXiv, 2021)

Associations between lifetime classic psychedelic use and markers of physical health. - Simonsson O; Sexton JD; Hendricks PS (Journal of psychopharmacology (Oxford, England), 2021)

Trial of Psilocybin versus Escitalopram for Depression. - Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ. (2021)

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. - Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM. (2021)

Cannabis-induced oceanic boundlessness. - Earleywine M; Ueno LF; Mian MN; Altman BR. (2021)

Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press) - Teixeira PJ; Johnson M; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris R. (PsyArXiv, 2021)

Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press) (PsyArXiv, 2021)

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. - Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; et al. (2021)

Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. - Dos Santos RG; Hallak JE; Baker G; Dursun S. (2021)

Complete mitochondrial genome sequence of Gymnopilus junonius. - Cho SE; Jo JW; Kwag YN; Lee H; Chung JW; Oh SH; Kim CS. (2021)

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. - Ross S; Agin-Liebes G; Lo S; Zeifman RJ; Ghazal L; Benville J; Franco Corso S; Bjerre Real C; Guss J; Bossis A; Mennenga SE. (2021)

A Rare Presentation of Anticholinergic Toxicity in a Young Patient Due to Over-The-Counter Cold Medicines. - Khan A; Singh G; Jacob J. (2021)

Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans - Musikaphongsakul P; Ya K; Subsoontorn P; Lohitnavy M. (F1000Res, 2021)

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review. - Zeifman RJ; Singhal N; Breslow L; Weissman CR. (2021)

Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials - Muthukumaraswamy S; Forsyth A; Lumley T. (PsyArXiv, 2021)

Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials (PsyArXiv, 2021)

The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype - Kozłowska U; Klimczak A; Wiatr K; Figiel M. (bioRxiv, 2021)

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. - Dos Santos RG; Bouso JC; Rocha JM; Rossi GN; Hallak JE. (2021)

Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity. - Fricke J; Sherwood AM; Halberstadt AL; Kargbo RB; Hoffmeister D. (2021)

Dose-response relationships of psilocybin-induced subjective experiences in humans. - Hirschfeld T; Schmidt TT. (2021)